Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization

Thrombosis Research

Volumn 121, Issue 1, 2007, Pages 25-32

  Pereira, Alexandre C ^a   Miyakawa, Ayumi A ^a   Lopes, Neuza H M ^a   Soares, Paulo R ^a   de Oliveira, Sergio A ^a   Cesar, Luiz A M ^a   Ramires, Jose F ^a   Hueb, Whady ^a   Krieger, Jose Eduardo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CABG; Homocysteine; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; MESSENGER RNA;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MORTALITY; ORGAN CULTURE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAPHENOUS VEIN GRAFT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; VASCULAR DISEASE;

AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DATA COLLECTION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HOMOCYSTINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MORTALITY; MYOCARDIAL REVASCULARIZATION; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE COMPLICATIONS; RNA, MESSENGER; SAPHENOUS VEIN;

EID: 35648952788     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.03.004     Document Type: Article

References (21)

1. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Powler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 (1991) 1149-1155
2. Fonseca V., Guba S.C., and Fink L.M. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 20 (1999) 738-759
3. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 (1997) 230-236
4. Anderson J.L., Muhlestein J.B., Horne B.F., Carlquist J.F., Bair T.L., Madsen T.E., et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 102 (2000) 1227-1232
5. Morita H., Kurihara H., Kuwaki T., Hamada C., Kitaoka M., Suzuki S., et al. Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb Haemost 84 (2000) 27-31
6. Kumbasar S.D., Dincer I., Ertas F., Gulec S., Erol C., Akyurek O., et al. Hyperhomocysteinemia and restenosis. J Cardiovasc Risk 8 (2001) 9-13
7. Schnyder G., Roffi M., Flammer Y., Pin R., and Hess O.M. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 23 (2002) 726-733
8. Jeremy J.Y., Shukla N., Angelini G.D., Day A., Wan I.Y., Talpahewa S.P., et al. Sustained increases of plasma homocysteine, copper, and serum ceruloplasmin after coronary artery bypass grafting. Ann Thorac Surg 74 (2002) 1553-1557
9. Lazzerini P.E., Capecchi P.L., Maccherini M., Diciolla F., Massai M.R., Guideri F., et al. Early and delayed increase in plasma homocysteine levels in heart transplanted patients. Transplant Proc 34 (2002) 1275-1278
10. Iwama Y., Mokuno H., Watanabe Y., Shimada K., Yokoi H., Daida H., et al. Relationship between plasma homocysteine levels and saphenous vein graft disease after coronary artery bypass grafts. Jpn Heart J 42 (2001) 553-562
11. Mudd S.H. Vascular disease and homocysteine metabolism. N Engl J Med 313 (1985) 751-753
12. Bos G.M., and den Heijer M. Hyperhomocysteinemia and venous thrombosis. Semin Thromb Hemost 24 (1998) 387-391
13. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
14. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93 (1996) 7-9
15. Christensen B., Frosst P., Lussier-Cacan S., Selhub J., Goyette P., Rosenblatt D.S., et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol (1997) 17569-17573
16. Kluijtmans L.A., Kastelein J.J., Lindemans J., Boers G.H., Heil S.G., Bruschke A.V., et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 96 (1997) 2573-2577
17. Pereira A.C., Schettert I.T., Morandini Filho A.A., Guerra-Shinohara E.M., and Krieger J.E. Methylenetetrahydrofolate reductase (MTHFR) C677T gene variant modulates the homocysteine folate correlation in a mild folate-deficient population. Clin Chim Acta 340 (2004) 99-105
18. Tran P., Leclerc D., Chan M., Pai A., Hiou-Tim F., Wu Q., et al. Multiple transcription start sites and alternative splicing in the methylenetetrahydrofolate reductase gene result in two enzyme isoforms. Mamm Genome 13 (2002) 483-492
19. Chen Z., Karaplis A.C., Ackerman S.L., Pogribny I.P., Melnyk S., Lussier-Cacan S., et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 10 (2001) 433-443
20. Botto N., Andreassi M.G., Rizza A., Berti S., Bevilacqua S., Federici C., et al. C677T polymorphism of the methylenetetrahydrofolate reductase gene is a risk factor of adverse events after coronary revascularization. Int J Cardiol 3 (2004) 341-345
21. Hueb W., Soares P.R., Gersh B.J., Cesar L.A., Luz P.L., Puig L.B., et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 43 (2004) 1743-1751